Why the study?
Minus 1 programmed ribosomal frameshifting is essential for critical biological processes, including SARS-CoV-2 replication, and efficient trans-modulation of the structured RNA element crucial to it could enable therapeutic applications.
CRISPR-Cas12a can effectively suppress SARS-CoV-2 programmed ribosomal frameshifting, offering a potential new therapeutic strategy for coronavirus infections.
No clinical application yet; leaves open CRISPR-Cas12a modulation of SARS-CoV-2 −1 PRF for further preclinical study.
Minus 1 programmed ribosomal frameshifting (−1 PRF) is a conserved translational regulation event essential for critical biological processes, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Efficient trans -modulation of the structured RNA element crucial to −1 PRF will endow the therapeutic application. Here, we demonstrate that CRISPR RNA can stimulate efficient −1 PRF. Assembled CRISPR-Cas12a, but not CRISPR-Cas9, complex further enhances −1 PRF efficiency through its higher capacity to stall translating ribosomes. We additionally perform CRISPR-Cas12a targeting to impair the SARS-CoV-2 frameshifting pseudoknot structure via a focused screening. We demonstrate that targeting CRISPR-Cas12a results in more than 70% suppression of −1 PRF in vitro and about 50% suppression in mammalian cells. Our results show the expanded function of the CRISPR-Cas12 system in modulating −1 PRF efficiency through stalling ribosomes and deforming frameshifting stimulatory signals, which could serve as a new strategy for future coronavirus pandemics.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: